Actemra® (Actemra®)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceTocilizumabTocilizumab
Similar drugsTo uncover
  • Actemra®
    concentrate d / infusion 
    Hoffmann-La Roche Ltd.     Switzerland
  • Actemra®
    solution PC 
    Hoffmann-La Roche Ltd.     Switzerland
    • Dosage form: & nbspSolution for subcutaneous administration.
    ATX: & nbsp

    L.04.A.C.07   Tocilizumab

    Form release / dosage:Solution for subcutaneous administration.
    Packaging:
    • solution for subcutaneous administration, 162 mg / 0.9 ml (syringe / autoinjector) x 4 (cardboard pack)
    Terms of leave from pharmacies:On prescription
    Registration number:LP-003186
    Date of registration:08.09.2015
    Date of cancellation:2020-09-08
    The owner of the registration certificate:Hoffmann-La Roche Ltd.Hoffmann-La Roche Ltd. Switzerland
    Manufacturer: & nbsp
    Representation: & nbspF.Hoffmann-La Roche Ltd. F.Hoffmann-La Roche Ltd. Switzerland
    Information update date: & nbsp01.10.2015
    Illustrated instructions
      Instructions
      Up